Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced HER2-Negative Breast Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT02586675
What this trial is testing

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

Who this might be right for
Breast CancerBreast Cancer - FemaleBreast Cancer - Male
H. Lee Moffitt Cancer Center and Research Institute 7
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07774624
What this trial is testing

Study of SKB103 in HER2-negative Breast Cancer

Who this might be right for
Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 140
Not applicableNot Yet RecruitingNCT07701070
What this trial is testing

SHIELD: Surveillance of HR+/HER2- : Implementing ESR1m Long-term Monitoring and Detection in 1L aBC

Who this might be right for
Advanced Breast Cancer
AstraZeneca 3,000
Testing effectiveness (Phase 2)Study completedNCT04596150
What this trial is testing

Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

Who this might be right for
NeoplasmsBreast NeoplasmsBreast Neoplasms, Triple-Negative+2 more
CytomX Therapeutics 125
Early research (Phase 1)Looking for participantsNCT05969041
What this trial is testing

Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors

Who this might be right for
Epithelial Tumors, Malignant
Myeloid Therapeutics 48
Large-scale testing (Phase 3)Active Not RecruitingNCT05306340
What this trial is testing

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Who this might be right for
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Genentech, Inc. 373
Early research (Phase 1)Looking for participantsNCT07318805
What this trial is testing

Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Breast CancerMetastatic Breast Cancer (HR+/ HER2-)Colorectal Cancer+2 more
Pfizer 260
Early research (Phase 1)Active Not RecruitingNCT03983954
What this trial is testing

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Who this might be right for
ER+ Breast CancerOvarian CancerCervical Squamous Cell Carcinoma+17 more
NeoTX Therapeutics Ltd. 120
Testing effectiveness (Phase 2)Looking for participantsNCT06495515
What this trial is testing

Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer

Who this might be right for
CANCERBRAEST CANCERLate Frontline
Tianjin Medical University Cancer Institute and Hospital 36
Early research (Phase 1)Study completedNCT02776917
What this trial is testing

Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer

Who this might be right for
Breast Neoplasms
Barbara Parker, MD 23
Large-scale testing (Phase 3)Not Yet RecruitingNCT07805135
What this trial is testing

HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer

Who this might be right for
HER2-Negative Advanced Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 430
Large-scale testing (Phase 3)Looking for participantsNCT06982521
What this trial is testing

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Who this might be right for
PIK3CA MutationHER2- Negative Breast CancerHormone Receptor Positive Tumor+3 more
Relay Therapeutics, Inc. 540
Testing effectiveness (Phase 2)UnknownNCT04571437
What this trial is testing

Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)

Who this might be right for
Breast CancerEstrogen Receptor-positive Breast CancerMetastatic Breast Cancer
Cairo University 204
Large-scale testing (Phase 3)Looking for participantsNCT07060807
What this trial is testing

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Who this might be right for
Breast Neoplasms
Merck Sharp & Dohme LLC 1,000
Testing effectiveness (Phase 2)Ended earlyNCT01272141
What this trial is testing

Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer

Who this might be right for
Breast NeoplasmsBreast CancerCancer of the Breast
Emory University 5
Large-scale testing (Phase 3)Active Not RecruitingNCT05077449
What this trial is testing

XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Xuanzhu Biopharmaceutical Co., Ltd. 300
Testing effectiveness (Phase 2)UnknownNCT04488107
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c

Who this might be right for
Breast Neoplasms
Ahon Pharmaceutical Co., Ltd. 78
Early research (Phase 1)Active Not RecruitingNCT02792114
What this trial is testing

T-Cell Therapy for Advanced Breast Cancer

Who this might be right for
Breast CancerMetastatic HER2-negative Breast
Memorial Sloan Kettering Cancer Center 186
Testing effectiveness (Phase 2)Looking for participantsNCT06907043
What this trial is testing

PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

Who this might be right for
Advanced Solid Tumors
Eikon Therapeutics 130
Testing effectiveness (Phase 2)Looking for participantsNCT07227233
What this trial is testing

Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.

Who this might be right for
Breast Cancer
University of California, San Diego 105
Next Page